Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 21, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,250,000 ordinary shares of 25 pence each.
- Purchase Price: 1,103.35 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.11% of total voting rights).
- Shares in Issue: 5,204,327,162 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,250,000 shares purchased on November 21, 2008. Consequently, the number of shares in issue was adjusted to 5,204,327,162. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the share repurchase (1,250,000 shares at 1,103.35 pence each).
- Confirm the updated share count of 5,204,327,162 for calculating ownership percentages under Disclosure and Transparency Rules.
- Note that 9.11% of total voting rights are held in Treasury and are excluded from the shares in issue.
- Recognize that this filing is a notification of a capital transaction and does not contain quarterly or annual financial results.